Hong Kong Stock Movement | Kiyang Pharmaceutical-B (02171.HK) rises over 4% again as CT1190B is approved for the treatment of R/R LBCL patients who have failed at least second-line standard treatments.

According to Zhitong Finance APP, CStone Pharmaceuticals-B (02171.HK) has increased by over 4%. As of the time of writing, it has risen by 4.03% to HKD 15.48, with a transaction volume of HKD 21,986,600.